Sequential Blood Level Monitoring of Basiliximab During Multisession Plasmapheresis in a Kidney Transplant Recipient

Nojima, Masanori; Yoshimoto, T; Nakao, Atsunori; Itahana, Reiko; Kyo, Masahiro; Hashimoto, Mitsuo; Shima, Hiroki

doi:10.1016/j.transproceed.2005.01.050

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…При этом значительное снижение концентрации базиликсимаба также происходит в результате нескольких сеансов двойной каскадной плазмофильтрации. [4]. Также, по мнению авторов, нет значительного влияния концентрации плазмафереза на концентрацию такролимуса в крови [5,6].…”

Section: Hemofiltration and Coupled Plasma Filtration Adsorption Impaunclassified

Hemofiltration and Coupled Plasma Filtration Adsorption Impact on Tacrolimus Blood Concentration in Renal Transplant Recipients

Vatazin

Зулькарнаев

Курчатова

et al. 2014

RJTAO

View full text Add to dashboard Cite

Aim. To study the effect of hemofi ltration and coupled plasma fi ltration adsorption on tacrolimus blood concentration in renal transplant recipients. Methods and results. The study included 8 renal transplant recipients. In these patients immediately after the operation was performed the coupled plasma fi ltration adsorption with hemofi ltration using a cartridge Mediasorb to reduce the severity of reperfusion injury. We have found that during this extracorporeal blood correction procedure there was statistically not signifi cant decrease of tacrolimus blood concentration. However, concentration of tacrolimus remained in the therapeutic range even after the procedure and it was not signifi cantly different from the control point С 0. Conclusion. Coupled plasma fi ltration adsorption is safe in renal transplant recipients and has no signifi cant impact on tacrolimus blood concentration. However, the downward trend in the concentration of tacrolimus in the course of these procedures, especially in continuous or semicontinuous mode, as well as in patients with low hematocrit and hypoalbuminemia, requires individual monitoring.

show abstract

Section: Hemofiltration and Coupled Plasma Filtration Adsorption Impaunclassified

Hemofiltration and Coupled Plasma Filtration Adsorption Impact on Tacrolimus Blood Concentration in Renal Transplant Recipients

Vatazin

Зулькарнаев

Курчатова

et al. 2014

RJTAO

View full text Add to dashboard Cite

show abstract

“…CD25 positive cells were appropriately surpressed. However, the concentration of basiliximab is reduced by more than 60% by a single session of plasmapheresis (Okechukwu et al 2001) or nearly 90% by multiple sessions (Nojima et al 2005).…”

Section: Drug Development and Pharmacological Propertiesmentioning

confidence: 99%

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Salis

Caccamo

Verzaro

et al. 2008

BTT

View full text Add to dashboard Cite

Basiliximab is a chimeric mouse-human monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor on activated T lymphocytes. It was shown in phase III trials to reduce the number and severity of acute rejection episodes in the fi rst year following renal transplantation in adults and children, with a reasonable cost-benefi t ratio. The drug does not increase the incidence of opportunistic infections or malignancies above baseline in patients treated with conventional calcineurin inhibitor-based immunosuppression. In the fi eld of renal transplantation, basiliximab does not increase kidney or patient survival, despite the reduction in the number of rejection episodes. Basiliximab may reduce the incidence of delayed graft function. In comparison with lymphocyte-depleting antibodies basiliximab appears to have equal effi cacy in standard immunological risk patients. Recently, IL-2 receptor monoclonal antibodies have been used with the objective of reducing or eliminating the more toxic elements of the standard immunosuppression protocol. Several trials have incorporated basiliximab in protocols designed to avoid or withdraw rapidly corticosteroids, as well as protocols which substitute target-of-rapamycin (TOR) inhibitors for calcineurin inhibitors.

show abstract

Monoclonal Antibodies in Solid Organ Transplantation

Pilch

Meadows

Alloway

2013

Pharmaceutical Biotechnology

View full text Add to dashboard Cite

Sequential Blood Level Monitoring of Basiliximab During Multisession Plasmapheresis in a Kidney Transplant Recipient

Cited by 7 publications

References 6 publications

Hemofiltration and Coupled Plasma Filtration Adsorption Impact on Tacrolimus Blood Concentration in Renal Transplant Recipients

Hemofiltration and Coupled Plasma Filtration Adsorption Impact on Tacrolimus Blood Concentration in Renal Transplant Recipients

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Monoclonal Antibodies in Solid Organ Transplantation

Contact Info

Product

Resources

About